FAPI-PET shows promise in head and neck cancer patients
AuntMinnie
JANUARY 26, 2024
In a comparative imaging trial, fibroblast activation protein inhibitor (FAPI)-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer, according to a study published January 25 in the Journal of Nuclear Medicine. The finding suggests that FAPI-PET/CT could serve as a sensitive, reliable, and reproducible imaging technique for these patients, in whom detection rates of primary tumors are low, noted Bingxin Gu, MD, of Fudan University in Shanghai, China, a
Let's personalize your content